3522集团新网站

CCT241161是一种口服有效的泛RAF抑制剂，对BRAF及NRAS突变型黑色素瘤表现出良好活性，并能抑制癌细胞增殖。

/

粉末-25~-15℃保存，有效期3年；溶于溶剂，-85~-65℃保存，有效期2年。

[1] Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. Erratum in: Cancer Cell. 2017 Mar 13;31(3):466. doi: 10.1016/j.ccell.2017.02.007. PMID: 25500121; PMCID: PMC4297292.